Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Cosmos Health Inc.
Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657
June 1, 2026
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
May 26, 2026
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
May 21, 2026
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders’ Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
May 21, 2026
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB’s Venture Debt Program
May 14, 2026
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
May 12, 2026
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
May 8, 2026
Cosmos Health Introduces Fort18 in the United States – A Men’s Sexual Stamina Supplement Expanding the 18 Series into Men’s Wellness
May 7, 2026
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
April 30, 2026
Cosmos Health Introduces the “18 Series” in the United States – A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
April 21, 2026
1
2
3
Next Page
→